AMENDMENTS TO THE CLAIMS

Please amend claims 1-48 as follows:

1. (Previously presented) A method of treating a patient suffering from or susceptible to an RSV infection, which method comprises administering to said patient an effective amount of a compound which is (a) a benzodiazepine derivative of the formula (I) or an N-oxide thereof or (b) a pharmaceutically acceptable salt thereof

wherein:

 R^1 represents C_{1-6} alkyl, aryl or heteroaryl;

 R^2 represents hydrogen or C_{1-6} alkyl;

each R^3 is the same or different and represents halogen, hydroxy, $C_{1\text{-}6}$ alkyl, $C_{1\text{-}6}$ alkoxy, $C_{1\text{-}6}$ alkylthio, $C_{1\text{-}6}$ haloalkyl, $C_{1\text{-}6}$ haloalkoxy, amino, mono($C_{1\text{-}6}$ alkyl)amino, di($C_{1\text{-}6}$ alkyl)amino, nitro, cyano, - CO_2R' , -CONR'R'', -NH-CO-R', -S(O)R', - $S(O)_2R'$, NH- $S(O)_2R'$, -S(O)NR'R'' or - $S(O)_2NR'R''$, wherein each R' and R' is the same or different and represents hydrogen or $C_{1\text{-}6}$ alkyl;

n is from 0 to 3;

 R^4 represents hydrogen or C_{1-6} alkyl;

X represents -CO-, -CO-NR'-, -S(O)- or -S(O)₂-, wherein R' is hydrogen or a C_{1-6} alkyl group; and

 R^5 represents an aryl, heteroaryl or heterocyclyl group, which group is substituted by a C_{1-6} hydroxyalkyl group or a -(C_{1-4} alkyl)- X_1 -(C_{1-4} alkyl)- X_2 -(C_{1-4} alkyl) group, wherein X_1 represents -O-, -S- or -NR'-, wherein R' represents H or a C_{1-4} alkyl group and X_2 represents - CO-, -SO- or -SO₂-, or R_5 represents - A_1 -Y- A_2 , wherein:

 A_1 is an aryl, heteroaryl, carbocyclyl or heterocyclyl group;

Y represents a direct bond or a C_{1-4} alkylene, -SO₂-, -CO-, -O-, -S- or -NR'- moiety, wherein R' is a C_{1-6} alkyl group; and

A₂ is an aryl, heteroaryl, carbocyclyl or heterocyclyl group.

- 2. (Previously presented) The method according to claim 1, wherein R^1 is C_{1-2} alkyl or phenyl.
- 3. (Previously presented) The method according to claim 1, wherein R² is hydrogen.
- 4. (Previously presented) The method according to claim 1 wherein R^3 is halogen, hydroxy, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} alkylthio, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, amino, mono(C_{1-4} alkyl)amino or di(C_{1-4} alkyl)amino.
- 5. (Previously presented) The method according to claim 4, wherein R^3 is fluorine, chlorine, bromine, C_{1-2} alkyl, C_{1-2} alkoxy, C_{1-2} alkylthio, C_{1-2} haloalkyl, C_{1-2} haloalkoxy, amino, mono(C_{1-2} alkyl)amino or di (C_{1-2} alkyl)amino.
- 6. (Previously presented) The method according to claim 1 wherein R^4 is hydrogen or C_{1-2} alkyl.
- 7. (Previously presented) The method according to claim 1 wherein X is -CO- or -CO-NR'- wherein R' represents hydrogen or a C_{1-2} alkyl group.
- 8. (Previously presented) The method according to claim 1, wherein R^5 is a 5- or 6-membered heterocyclyl or heteroaryl ring which is substituted by a C_{1-6} hydroxyalkyl group or a -(C_{1-4} alkyl)- X_1 -(C_{1-4} alkyl)- X_2 -(C_{1-4} alkyl) group, wherein X_1 and X_2 are as defined in claim 1.
- 9. (Previously presented) The method according to claim 8, wherein R^5 is a 5- or 6-membered heteroaryl group which is substituted by a -CH₂-OH or -(C₁₋₄ alkyl)-NR'-(C₁₋₄ alkyl)-S(O)₂-(C₁₋₄ alkyl) substituent, wherein R is hydrogen or C₁₋₂ alkyl.
- 10. (Previously presented) The method according to claim 1, wherein A_1 is an aryl or heteroaryl group.

- 11. (Previously presented) The method according to claim 10, wherein A_1 is a phenyl group, a monocyclic 5- or 6-membered heteroaryl group or a 5- to 6-membered heteroaryl group fused to a monocyclic oxo-substituted 5- to 6-membered heterocyclyl group.
- 12. (Previously presented) The method according to claim 1 wherein A_1 is unsubstituted or substituted by 1 or 2 substituents selected from halogen, cyano, nitro, C_{1-4} alkyl, C_{1-4} haloalkyl and C_{1-4} alkoxy substituents.
- 13. (Previously presented) The method according to claim 1, wherein Y represents a direct bond, a C_{1-2} alkylene group, -SO₂- or -O-.
- 14. (Previously presented) The method according to claim 1, wherein A_2 is a phenyl, 5- to 6-membered heterocyclyl or C_{3-6} cycloalkyl group.
- 15. (Previously presented) The method according to claim 1, wherein when A_2 is a heterocyclyl group it is attached to the moiety Y via a N atom.
- 16. (Previously presented) The method according to claim 1, wherein A_2 is unsubstituted or is substituted by 1 or 2 substituents which are selected from C_{1-4} alkyl and halogen substituents when A_2 is a heteroaryl or aryl group and which are selected from C_{1-4} alkyl, halogen and oxo substituents when A_2 is a carbocyclic or heterocyclyl group.
- 17. (Previously presented) The method according to claim 1, wherein A_2 is a piperazinyl, pyridyl, morpholinyl, pyrrolidinyl, piperidinyl, pyrazinyl, cyclopropyl, phenyl or S,S-dioxothiomorpholino group, which is unsubstituted or substituted by a C_{1-2} alkyl group.
- 18. (Previously presented) The method according to claim 1, wherein the benzodiazepine derivative of formula (I) is a benzodiazepine derivative of formula (Ia):

$$\begin{array}{c}
H \\
N \\
N \\
H
\end{array}$$
(Ia)

wherein:

X is -CO- or -CO-NH-; and

 R^5 is a 5- to 6- membered heteroaryl group, for example a furanyl group, which is substituted by -CH₂-OH or -(C₁₋₄ alkyl)-N(CH₃)-(C₁₋₄ alkyl)-SO₂-(C₁₋₄ alkyl) or R^5 represents – A₁-Y-A₂, wherein: A₁ is a phenyl, pyridyl, furanyl, thiazolyl, oxazolyl, isoxazolyl, thienyl or lH-imidazo[4,5-b]pyridin-2-(3H)-one moiety, which is unsubstituted or substituted by 1 or 2 substituents selected from halogen, cyano, C₁₋₂ alkyl, C₁₋₂ haloalkyl and C₁₋₂ alkoxy substituents;

Y is a direct bond, a C₁₋₂ alkylene group, -SO₂- or -O-; and

 A_2 is a piperazinyl, pyridyl, morpholinyl, pyrrolidinyl, piperidinyl, pyrazinyl, cyclopropyl, phenyl or S,S-dioxo-thiomorpholino group, which is unsubstituted or substituted by a C_{1-2} alkyl group.

- 19. (Previously presented) The method according to claim 1, wherein the medicament is for use in treating a patient who is a child under two years of age, an adult suffering from asthma, chronic obstructive pulmonary disorder (COPD) or immunodeficiency, an elderly person or a person in a long term care facility.
- 20. (Previously presented) The method according to claim 19 wherein said child suffers from chronic lung disease.
- 21. (Previously presented) The method according to claim 1 wherein the medicament is for use in preventing RSV infection in an infant less than six years of age who was born after 32 weeks of gestation or less.
- 22. (Previously presented) The method according to claim 1, wherein the medicament is suitable for intranasal or intrabronchial administration.

- 23. (Previously presented) The method according to claim 1, wherein the medicament further comprises an anti-inflammatory compound or an anti-influenza compound.
- 24. (Previously presented) The method according to claim 23 wherein the anti-inflammatory compound is budesonide or fluticasone.
- 25. (Previously presented) The method according to claim 23 wherein the anti-inflammatory compound is a leukotriene antagonist, phosphodiesterase 4 inhibitor or TNF alpha inhibitor.
- 26. (Previously presented) The method according to claim 23 wherein the anti-inflammatory compound is an interleukin 8 or interleukin 9 inhibitor.
- 27. (Previously presented) The method according to claim 1 wherein the medicament is coadministered with an anti-inflammatory compound, wherein the anti-inflammatory compound is selected from the group consisting of budesonide, fluticasone, a leukotriene antagonist, phosphodiesterase 4 inhibitor, TNF alpha inhibitor, an interleukin 8 inhibitor and an interleukin 9 inhibitor.
- 28. (Canceled)
- 29. (Previously presented) The method according to claim 1, wherein said patient is selected from the group consisting of a child under two years of age, an adult suffering from asthma, chronic obstructive pulmonary disorder (COPD) or immunodeficiency, an elderly person, a person in a long term care facility, a child under two years of age that suffers from chronic lung disease, and an infant less than six years of age who was born after 32 weeks of gestation or less.
- 30. (Previously presented) The method according to claim 29, wherein said compound is administered intranasally or intrabronchially.
- 31. (Withdrawn) An inhaler or nebuliser containing a medicament which comprises
 - (a) a compound as defined in claim 1, and

- (b) a pharmaceutically acceptable carrier or diluent.
- 32. (Withdrawn) A product comprising a compound as defined in claim 1 and an anti-inflammatory compound selected from the group consisting of budesonide, fluticasone, a leukotriene antagonist, a phosphodiesterase 4 inhibitor, a TNF alpha inhibitor, an interleukin 8 inhibitor and an interleukin 9 inhibitor, or an anti-influenza compound.
- 33. (Previously presented) The method of claim 1, wherein the patient suffers from concomitant RSV and influenza infections.
- 34. (Previously presented) The method of claim 1, wherein the patient suffers from human metapneumo virus, measles, parainfluenza viruses, mumps, yellow fever virus (B5 strain), Dengue 2 virus or West Nile virus.
- 35. (Withdrawn) A compound which is (a) a benzodiazepine derivative of formula (Ib) or an N-oxide thereof, or (b) a pharmaceutically acceptable salt thereof

$$(R^3)_n \xrightarrow{\text{II}} N \xrightarrow{\text{N}} N - X - R^5$$

$$R^1 \qquad (Ib)$$

wherein R₁, R₃, n, R₄, X and R₅ are as defined in claim 1.

- 36. (Withdrawn) A compound according to claim 35, wherein R_1 is an unsubstituted phenyl group.
- 37. (Withdrawn) A compound according to claim 35, wherein when A_1 is a heteroaryl group, it is other than a 5-methyl-isoxazolyl moiety.
- 38. (Withdrawn) A compound according to claim 1, wherein A_1 is an arylor heteroaryl moiety.

- 39. (Withdrawn) A compound according to claim 1, wherein X is -CO- or -CO-NR'-, wherein R' is as defined in claim 1, provided that when X is -CO-NR'-, the moiety $-A_1$ -Y- A_2 is -phenyl-O-phenyl.
- 40. (Withdrawn) A compound according to claim 1, wherein A_2 is other than a 4- to 10-membered saturated cycloalkyl ring, in which one of the carbon atoms is replaced by a N atom.
- 41. (Withdrawn) A compound according to claim 1, wherein A_2 is a piperazinyl, pyridyl, pyrrolidinyl, pyrazinyl, cyclopropyl, phenyl or S,S-dioxo- thiomorpholino group which is unsubstituted or is substituted by a C_{1-2} alkyl group.
- 42. (Withdrawn) A compound according to claim 35, wherein the benzodiazepine derivative of the formula (Ib) is:
- 6-(4-Methyl-piperazin-1-yl)-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4] diazepin-3-yl)-nicotinamide;
- 3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-5'-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;
- (S)-2-(1,1-Dioxo-lλ6-thiomorpholin-4-yl)-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl-benzamide;
- (S)-2-Chloro-4-morpholin-4-yl-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4] diazepin-3-yl)-benzamide;
- $(S)-2-(1,1-Dioxo-1\lambda 6-thiomorpholin-4-yl)-4-fluoro-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl-benzamide;$
- (S)-5-Chloro-2-(1, 1-dioxo-1λ6-thiomorpholin-4-yl)-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-benzamide;
- (S)-2-(l,l-Dioxo-lλ6-thiomorpholin-4-yl)-5-fluoro-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-benzamide;
- (S)-5-(4-Methyl-piperazin-l-ylmethyl)-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-amide;
- (S)-5-Pyrrolidin-l-ylmethyl-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-amide;

- (S)-5-Piperidin-1-ylmethyl-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;
- (S)-5-Dimethylaminomethyl-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-amide;
- (S)-4-Fluoro-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-2-piperidin-1-yl-benzamide;
- (S)-4-Fluoro-2-morpholino-4-yl-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4] diazepin-3-yl)-benzamide;
- (S)-4-Cyano-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-2-pyrrolidin-1-yl-benzamide;
- (S)-4-Cyano-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][l,4]diazepin-3-yl)-piperidine-1 -yl-benzamide;
- (S)-N-(2-Oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-2-pyrrolidin-l-yl-4-trifluoromethyl-benzamide;
- (S)-N-(2-Oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-2-piperidin-l-yl-4-trifluoromethyl-benzamide;
- (S)-2-Morpholin-4-yl-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-4-trifluoromethyl-benzamide;
- $(S)-N-(2-Oxo-5-\rho henyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-2-pyrrolidin-l-yl-5-trifluoromethyl-benzamide;$
- (S)-2-Morpholin-4-yl-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-5-trifluoromethyl-benzamide;
- (S)-2-Morpholin-4-yl-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-nicotinamide;
- $(S)-2-(l,l-Dioxo-l\lambda 6-thiomorpholin-4-yl)-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-nicotinamide;$
- (S)-2-(l,l-Dioxo-lλ6-thiomorphholin-4-yl)-3-methyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;
- (S)-2-(1,1-Dioxo-1λ6-thiomorpholin-4-yl)-4-methyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;
- $(S)-2-(1,1-Dioxo-1\lambda 6-thiomorpholin-4-yl)-6-methyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;$

- (S)-2-Chloro-6-(I,I-dioxo- $I\lambda$ 6-thiomorpholin-4-yl)-N-(2-oxo-5-phenyl-2,3-dihydro-IH-benzo[e][1,4]diazepin-3-yl)-benzamide;
- (S)-3-Cyclopropyl-2-oxo-2,3-dihydro-imidazo[4,5-b]pyridine-l-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-amide;
- (S)-3-(4-Methyl-piperazine-l-sulfonyl)-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-benzamide;
- (S)-4-(4-Methyl-piperazin-l-yl)-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4] diazepin-3-yl)-benzamide;
- (S)-N-(2-Oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-3-(piperidine-l-sulfonyl)-benzamide;
- (S)-3-(Morpholine-4-sulfonyl)-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4] diazepin-3-yl)-benzamide;
- (S)-5-Morpholin-4-ylmethyl-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-amide;
- (S)-5-Hydroxymethyl-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-amide;
- (S)-5-(l,l-Dioxo-lλ6-thiomorpholin-4-ylmethyl)-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-amide;
- (S)-2-Chloro-4-(l,l-dioxo-lλ6-thiomorpholin-4-yl)-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-benzamide;
- (S)-2-Chloro-5-(l,l-dioxo-lλ6-thiomorpholin-4-yl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;
- (S)-5-{[(2-Methanesulfonyl-ethyl)-methyl-amino]-methyl}-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl-amide;
- (S)-2-Pyridin-3-yl-thiazole-4-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-amide;
- (S)-2-Pyridin-4-yl-thiazole-4-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;
- (S)-4-Methyl-2-pyrazin-2-yl-thiazole-5-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;
- (S)-2-Morpholin-4-ylmethyl-furan-3-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

- (S)-3-Morpholin-4-ylmethyl-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3-yl)-benzamide;
- (S)-5-Morpholin-4-ylmethyl-isoxazole-3-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-amide;
- (S)-3-Morpholin-4-ylmethyl-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-amide;
- (S)-5-Pyridin-2-yl-thiophene-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-amide;
- (S)-2-Methyl-4-(morpholin-4-sulfonyl)-furan-3-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-amide;
- (S)-6-Morpholin-4-yl-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-nicotinamide;
- (S)-3-Morpholin-4-ylmethyl-thiophene-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;
- (S)-5-Morpholin-4-ylmethyl-thiophene-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-amide;
- 2-Morpholin-4-yl-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-benzamide;
- (S)-5-Phenyl-oxazole-4-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4] diazepin-3-yl)-amide; or
- l-(2-Oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-3-(4-phenoxy-phenyl)-urea.
- 43. (Withdrawn) A compound according to claim 35 for use in a method of treating the human or animal body.
- 44. (Withdrawn) A pharmaceutical composition comprising a compound according to claim 35, and a pharmaceutically acceptable diluant or carrier.
- 45. (Withdrawn) A composition according to claim 44 comprising an optically active isomer of a compound according to claim 35.

- 46. (Withdrawn) A composition according to claim 44 which is in the form of a tablet, troche, lozenge, aqueous or oily suspension, dispersible powders or granules.
- 47. (Currently amended) A method [[of]] according to claim 1, wherein the compound is (S)-4-Fluoro-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-2-piperidin-1-yl-benzamide; (S)-4-Fluoro-2-morpholino-4-yl-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3-yl)-benzamide; or (S)-2-Chloro-4-morpholin-4-yl-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3-yl)-benzamide.
- 48. (New) A method according to claim 47, wherein the compound is (S)-4-Fluoro-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][1,4]diazepin-3-yl)-2-piperidin-1-yl-benzamide.